This abstract presented at the 39th Annual meeting of the American Society of Nephrology, held in Nov 2006 at San Diego, CA. (PUB 381, 897A, V17, 2006)

Title: Effect of feeding Kibow Biotics® to cats and dogs in kidney failure

Natarajan Ranganathan, Ph D1, Beena G Patel, Ph D1, Pari Ranganathan, MSMTASCP1, Rahul Dheer, BS1, Richard Pamquist, DVM2 and Gary Van Engelenberg, DVM, CVA3. 1Microbiology, Kibow Biotech Inc, Newtown Square, PA, United States; 2Veterinary, Centinela Animal Hospital, Inglewood, CA, United States and 3Veterinary, Iowa Veterinary Acupuncture Clinic, Des Moines, IA, United States.

Basic biological research using animal models of human disease may provide information on the value of a specific product as a potential disease treatment. Surgical uremic models of 5/6th nephrectomized rats and minipigs enhanced our understanding of the progression and pathophysiological processes leading to chronic kidney disease (CKD). These models have provided insights into the concept of removal of uremic solutes which accumulates due to kidney failure. Previously, we reported that feeding of probiotics has benefited rats and pigs with renal insufficiency, indicating that reduction in the level of uremic solutes may improve quality of life.

Kibow Biotics® is a mixture of probiotics (live microbes when ingested exert health benefits) selectively screened for enzymatic activity capable of reducing targeted uremic toxins. When Kibow Biotics® was fed to surgical model of rats and minipig, both blood urea nitrogen (BUN) and serum creatinine(Scr) levels was shown to be stabilized in rats and significantly decreased in BUN level (p=0.001) in minipigs, when compared to the placebo group.

Two independent veterinarians initiated trials of Kibow Biotics® for kidney failure cats and dogs of both genders and of varying body weights. Both BUN and Scr levels declined during therapy; in cats (n=7), (BUN 54±13.0 to 45.1±12.0 mg/dl, while Scr (4.0±1.9 to 2.9±0.7 mg/dl) and in dogs (n=6) (BUN 64.7±35.4 to 30.4±17.7 mg/dl), and Scr (2.6±1.3 to 2.0±1.5 mg/dl). No adverse effects were noted in any animals during 2-6 months of study. Pet owners consistently reported significant improved mobility, appetite and overall quality of life. Word of mouth enthusiasm among owners of pets with CKD resulted in substantive increased sales of Kibow Biotics® that has more than 500 cats and dogs over the last 10 months.

Thus feedings of Kibow Biotics® to cats and dogs supports the value of probiotic treatment that may have application in humans.